Substituted pyrido [3′, 2′: 4, 5] thieno [3, 2-D] pyrimidines and pyrido [3′, 2′: 4, 5] furo [3, 2-D] pyrimidines used as inhibitors of the PDE-4 and/or the release of TNF-ALPHA

US8058285B2 · kind B2 · utility

Assignee

• THE MEDICINES COMPANY (LEIPZIG) GMBH · DE

Inventors

• Claudia Reichelt · Leipzig, DE
• Alexander Ludwig · Leipzig, DE
• Alexander Schulze · Bad Liebenwerda, DE
• Mohammed Daghish · Leipzig, DE
• Siegfried Leistner · Leipzig, DE
• Andreas Krödel · Leipzig, DE
• Jochen Heinicke · Leipzig, DE

Key dates

• Filing date: Jan 22, 2007
• Grant date: Nov 15, 2011
• Expiry date: Apr 14, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D495/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to compounds of general formula (I); 1a, 1 b, 1 c and 1 d. The invention also relates to a method for the production thereof, pharmaceutical preparations containing said compounds and/or physiologically compatible salts thereof which can be produced therefrom and/or solvates thereof, and to the pharmaceutical use of said compounds, salts or solvates thereof as inhibitors of phosphodiesterase 4. The compounds comprise active ingredients for the treatment of diseases which can have a positive influence by inhibiting the activity of phosphodiesterase 4 and/or TNFα-release, for example, in lymphocytes, eosinophile and basophile granulocytes, macrophages and mastocytes.